1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program

1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program

This analysis aimed to evaluate the effect of 1- versus 3-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in older patients. Data from 3 prospective, single-arm studies (XIENCE Short DAPT Program), including patients with high bleeding risk successfully treated...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of cardiology 2024-03, Vol.214, p.94-104
Hauptverfasser: Sardella, Gennaro, Spirito, Alessandro, Sartori, Samantha, Angiolillo, Dominick J., Vranckx, Pascal, Hernandez, Jose M. De la Torre, Krucoff, Mitchell W., Bangalore, Sripal, Bhatt, Deepak L., Campo, Gianluca, Cao, Davide, Chehab, Bassem M., Choi, James W., Feng, Yihan, Ge, Junbo, Godfrey, Katherine, Hermiller, James, Kunadian, Vijay, Makkar, Raj R., Maksoud, Aziz, Neumann, Franz-Josef, Picon, Hector, Saito, Shigeru, Thiele, Holger, Toelg, Ralph, Varenne, Olivier, Vogel, Birgit, Zhou, Yujie, Valgimigli, Marco, Windecker, Stephan, Mehran, Roxana
Format: Artikel
Sprache:eng
Schlagworte:
Age
Anemia
Antiplatelet therapy
Bleeding
Cardiovascular disease
Consortia
Coronary vessels
Creatinine
Death
dual antiplatelet therapy
elderly
Heart attacks
Hemoglobin
high bleeding risk
Implants
Ischemia
Mortality
Myocardial infarction
percutaneous coronary intervention
Risk
Stents
Stroke
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This analysis aimed to evaluate the effect of 1- versus 3-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in older patients. Data from 3 prospective, single-arm studies (XIENCE Short DAPT Program), including patients with high bleeding risk successfully treated with an everolimus-eluting stent (XIENCE, Abbott) were analyzed. DAPT was discontinued at 1 or at 3 months in patients free from ischemic events and adherent to DAPT. Patients were stratified according to age (≥75 and
ISSN:0002-9149
1879-1913
1879-1913
DOI:10.1016/j.amjcard.2023.12.049